These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25724400)

  • 1. Competing risks model in screening for preeclampsia by maternal characteristics and medical history.
    Wright D; Syngelaki A; Akolekar R; Poon LC; Nicolaides KH
    Am J Obstet Gynecol; 2015 Jul; 213(1):62.e1-62.e10. PubMed ID: 25724400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Competing-risks model in screening for pre-eclampsia in twin pregnancy by maternal characteristics and medical history.
    Francisco C; Wright D; Benkő Z; Syngelaki A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Oct; 50(4):501-506. PubMed ID: 28508528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competing-risks model for prediction of small-for-gestational-age neonate from maternal characteristics and medical history.
    Papastefanou I; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Aug; 56(2):196-205. PubMed ID: 32573831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive performance of the competing risk model in screening for preeclampsia.
    Wright D; Tan MY; O'Gorman N; Poon LC; Syngelaki A; Wright A; Nicolaides KH
    Am J Obstet Gynecol; 2019 Feb; 220(2):199.e1-199.e13. PubMed ID: 30447210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
    O'Gorman N; Wright D; Syngelaki A; Akolekar R; Wright A; Poon LC; Nicolaides KH
    Am J Obstet Gynecol; 2016 Jan; 214(1):103.e1-103.e12. PubMed ID: 26297382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
    Gallo DM; Wright D; Casanova C; Campanero M; Nicolaides KH
    Am J Obstet Gynecol; 2016 May; 214(5):619.e1-619.e17. PubMed ID: 26627730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
    Tsiakkas A; Saiid Y; Wright A; Wright D; Nicolaides KH
    Am J Obstet Gynecol; 2016 Jul; 215(1):87.e1-87.e17. PubMed ID: 26875953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competing-risks model in screening for pre-eclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeks' gestation.
    Francisco C; Wright D; Benkő Z; Syngelaki A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Nov; 50(5):589-595. PubMed ID: 28556556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-stage screening for preterm preeclampsia at 11-13 weeks' gestation.
    Wright A; Wright D; Syngelaki A; Georgantis A; Nicolaides KH
    Am J Obstet Gynecol; 2019 Feb; 220(2):197.e1-197.e11. PubMed ID: 30414394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revised competing-risks model in screening for pre-eclampsia in twin pregnancy by maternal characteristics and medical history.
    Benkő Z; Chaveeva P; de Paco Matallana C; Zingler E; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Nov; 54(5):617-624. PubMed ID: 31364214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A competing risks model in early screening for preeclampsia.
    Wright D; Akolekar R; Syngelaki A; Poon LC; Nicolaides KH
    Fetal Diagn Ther; 2012; 32(3):171-8. PubMed ID: 22846473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history.
    Poon LC; Wright D; Rolnik DL; Syngelaki A; Delgado JL; Tsokaki T; Leipold G; Akolekar R; Shearing S; De Stefani L; Jani JC; Plasencia W; Evangelinakis N; Gonzalez-Vanegas O; Persico N; Nicolaides KH
    Am J Obstet Gynecol; 2017 Nov; 217(5):585.e1-585.e5. PubMed ID: 28784417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations.
    O'Gorman N; Wright D; Poon LC; Rolnik DL; Syngelaki A; de Alvarado M; Carbone IF; Dutemeyer V; Fiolna M; Frick A; Karagiotis N; Mastrodima S; de Paco Matallana C; Papaioannou G; Pazos A; Plasencia W; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Jun; 49(6):756-760. PubMed ID: 28295782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The competing risk approach for prediction of preeclampsia.
    Wright D; Wright A; Nicolaides KH
    Am J Obstet Gynecol; 2020 Jul; 223(1):12-23.e7. PubMed ID: 31733203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
    Tsiakkas A; Mendez O; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Apr; 47(4):478-83. PubMed ID: 26582564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of large-for-gestational-age neonates: screening by maternal factors and biomarkers in the three trimesters of pregnancy.
    Frick AP; Syngelaki A; Zheng M; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):332-9. PubMed ID: 26446185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal cardiovascular function at 35-37 weeks' gestation: relation to maternal characteristics.
    Guy GP; Ling HZ; Garcia P; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Jan; 49(1):39-45. PubMed ID: 27671837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uterine artery pulsatility index at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
    O'Gorman N; Tampakoudis G; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 May; 47(5):565-72. PubMed ID: 26582756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal serum alpha-fetoprotein at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
    Bredaki FE; Matalliotakis M; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Apr; 47(4):466-71. PubMed ID: 26582719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical risk assessment in early pregnancy for preeclampsia in nulliparous women: A population based cohort study.
    Sandström A; Snowden JM; Höijer J; Bottai M; Wikström AK
    PLoS One; 2019; 14(11):e0225716. PubMed ID: 31774875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.